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We examined the anti-inﬂammatory eﬀects of the combination of thyme and oregano essential oil dietary administered at three
concentrations (0.4% thyme and 0.2% oregano oils; 0.2% thyme and 0.1% oregano oils; 0.1% thyme and 0.05% oregano oils)
on mice with TNBS-induced colitis. Treatment of colitic animals with the essential oils decreased the mRNA levels of pro-
inﬂammatory cytokines IL-1β, IL-6, GM-CSF, and TNFα, especially after application of the medium dose. The medium dose
of the essential oils signiﬁcantly lowered the amount of IL-1β and IL-6 proteins too. Moreover, administration of the medium dose
decreased the mortality rate, accelerated the body weight gain recovery, and reduced the macroscopic damage of the colonic tissue.
Our results indicate that combined treatment with appropriate concentrations of thyme and oregano essential oils can reduce the
production of proinﬂammatory cytokines, and thereby attenuate TNBS-induced colitis in mice.
Copyright © 2007 Alexandra Bukovsk´ a et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Intestinalinﬂammatorydiseasesareaseriousprobleminhu-
man as well as veterinary medicine. The etiology of these
diseases is often multifactorial and the underlying molecular
mechanisms are poorly understood [1]. The current medici-
naltherapiesforinﬂammatorygutdiseasesinvolvetreatment
with nonsteroidal anti-inﬂammatory drugs, antibiotics, cor-
ticosteroids, and immunosuppressant, but the application of
thesedrugsislimitedduetotheirtoxicityandsideeﬀects[2].
Therefore,thereisanincreasedinterestinﬁnding analterna-
tive treatment with fewer side eﬀects.
There is evidence supporting the therapeutic usefulness
of oral administration of various plant extracts in inﬂam-
matory diseases of the gut. Experimental data obtained in
mouse and rat models of colitis suggest that the beneﬁcial
eﬀects of the plant extracts could be mediated by their eﬀects
on mucosal cytokines production or/and action [3–9]. In-
creased levels of proinﬂammatory cytokines [IL-1, IL-6, IL-
8, TNFα, IL-12, and IFNγ] were found in inﬂamed intestinal
mucosa in various animal models and humans [10–13], as
well as in farm animals [14, 15].
Thyme(ThymusvulgarisL.)andoregano(Origanumvul-
gare L.) are aromatic plants of the Mediterranean ﬂora com-
monly used as spices and for medicinal purposes. Like other
various Thymus species, thyme is traditionally used for its
antiseptic, antispasmodic, and antitussive eﬀects. Further-
more, thyme possesses antimicrobial, antifungal, antioxida-
tive, and antiviral properties [16–19]. The essential oil de-
rived from thyme (T. vulgaris L.) is a mixture of monoter-
penes and one of the main compounds of this oil is a natural
terpenoid thymol [20]. Thymol exhibits multiple biological
activities including anti-inﬂammatory [21], immunomodu-
lating [22], antioxidant [23], antibacterial [24, 25], antifun-
gal[26],andfreeradicalscavengingproperties[27].Oregano
is recognized for its potential therapeutic role because of
its diaphoretic, carminative, antispasmodic, antiseptic, and
tonicproperties.Oregano,(OriganumsyriacumL.)similarto
thyme, evinces antioxidant and antimicrobial activities [28]
and some reports deal with its antimutagenic and anticar-
cinogenic eﬀects [29]. Origanum essential oil is obtained by
steam distillation of O. vulgare and its major compounds are
carvacrol and thymol [30]. Origanum essential oil is known
to possess antimicrobial, antifungal, and antioxidant activi-
ties [31, 32].
The aim of our study was to examine possible beneﬁcial
eﬀects of thyme and oregano essential oils on intestinal in-
ﬂammation. The results of our preliminary experiment sug-
gested that the administration of thyme oil in combination
with oregano oil could be more eﬀective in improvement of2 Mediators of Inﬂammation
Table 1: Experimental groups of animals.
Treatment
Group A Mice with TNBS-induced colitis fed with 0.4%—4000ppm (wt/wt)—thyme oil + 0.2%—2000ppm (wt/wt)—oregano oil
Group B Mice with TNBS-induced colitis fed with 0.2%—2000ppm (wt/wt)—thyme oil + 0.1%—1000ppm (wt/wt)—oregano oil
Group C Mice with TNBS-induced colitis fed with 0.1%—1000ppm (wt/wt)—thyme oil + 0.05%—500ppm (wt/wt)—oregano oil
Group D Mice with TNBS-induced colitis
Group E Sham-treated mice
trinitrobenzene sulphonic acid (TNBS)-induced colitis than
the separate administration of these essential oils. In the
present study, we evaluated further the eﬀect of administra-
tion of three diﬀerent doses of thyme and oregano oil com-
bination on TNBS-induced colitis in mice.
2. MATERIALS AND METHODS
2.1. Animalsandtreatment
Male 7-week-old Balb/c mice weighing 18–25g were pur-
chased from Velaz (Prague, Czech Republic). The animals
were maintained under standard conditions of temperature
(21 ± 1◦C), relative humidity (55 ± 10%), and 12 hours/12
hours light/dark cycle. All mice were housed in speciﬁc
pathogen-free conditions. All animal experimentations were
reviewed and approved by the Ethical Committee of the In-
stitute of Animal Physiology.
After a period of adaptation, weight-matched animals
were randomized into ﬁve groups: group A (20.2 ± 0.971g),
group B (20.6 ±0.75g), and group C (20.71 ±0.844g), mice
with TNBS-induced colitis treated with three diﬀerent doses
(see Table 1) of thyme and oregano oil combination; group
D( 2 1 .03 ± 1.025g), mice with TNBS-induced colitis; group
E( 1 8 .74 ±1.189g), sham-treated mice.
Thyme aromatic oil (Thymi aetheroleum-Ph.Eur. 4) and
oregano aromatic oil (Origani aetheroleum)w e r ep u r c h a s e d
from Calendula, (Nov´ aL ’ u b o vˇ na, Slovakia; thyme aromatic
oil: lot 5-015-003-10-04; oregano aromatic oil: lot 5-027-
007-10-04). The thyme aromatic oil contained about 48%
of. p-cymene and 24% of thymol, and the oregano aromatic
oil contained about 55% of carvacrol. 2,4,6-trinitrobenzene
sulphonic acid (TNBS) was purchased from Fluka Chemie
(Buchs, Switzerland). The thyme oil and oregano oil were
mixed with the diet at concentrations as shown in Table 1.
Both aromatic oils were suspended in edible soya oil (Br¨ olio,
Hamm, Germany) and added to powdery commercial ro-
dent diet (diet for laboratory mice and rats SPF, M1; Fran-
tisek Machal, Ricmanice, Czech Republic). In the TNBS and
sham groups, edible soya oil was mixed with the powdery ro-
dent diet at a concentration of 1% (wt/wt). Diets were fed
ad libitum throughout the experiment, starting 6 days before
administration of TNBS.
2.2. Inductionofcolitis,samplepreparation,
macroscopicalandhistologicalassessment
The mice were anesthetized with ketamine and xylazine,
and colitis was induced by intrarectal administration of
120mg/kg of the hapten reagent TNBS (Fluka Chemie) in
50% ethanol, and they were then kept in a vertical posi-
tion for 30 seconds. The sham group received 50% ethanol
alone using the same technique. The total injection vol-
ume was 30μL. Development of colitis was assessed daily by
measurement of body weight. The mortality rate was ob-
served during this study. The mice were killed by cervical
dislocation 7 days after TNBS administration. The colons
were removed, cut longitudinally, and cleared of fecal ma-
terial with gentle spray of 0.9% saline solution. The extent
of mucosal damage was assessed using the colon macro-
scopic scoring system adapted from Wallace et al. [33]. Ul-
ceration : (1) focal hyperemia, no ulcer; (2) ulceration, no
hyperemia/bowel wall thickening; (3) ulceration, inﬂamma-
tion at one site; (4) ulceration, inﬂammation at 2 or more
sites; (5) major injury > 1cm; 6–10 major damage > 2cm.
Adhesion: (1) minor (colon easily separated from other tis-
sue); (2) major. Diarrhea:( 1 ) ;B o w e lw a l lt h i c k e n i n g :( 1 ) .
Representative samples from each experimental group were
histologically evaluated. Colon tissues were ﬁxed in 4% for-
malin in 0.1 M phosphate buﬀer, dehydrated with increas-
ing concentrations of ethanol, embedded in paraﬃn, and
sectioned. Sections (4–6μm thick) were mounted on slides,
cleared, hydrated, and stained with hematoxylin and eosin.
The slides were examined and photographed with an Olym-
pus BX51 microscope (Olympus, Japan). Strips of colonic
tissue (15–30mg from segments most intensively aﬀected
by the inﬂammation) were cut out, immersed in liquid
nitrogen, and kept at −70◦C until the cytokine measure-
ment.
2.3. Real-timeRT-PCRquantiﬁcationof
cytokinemRNAexpression
Total RNA was isolated from the mouse colon (about 15mg
of tissue for each sample) with TRIzol reagent (Invitrogen
Life Technologies, Karlsruhe, Germany) according to the
manufacturer’s instructions. Total RNA preparations were
then cleaned and DNase I was treated with RNeasy Micro
Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol. In order to quantify total RNA extracted
from each sample, optical density at 260nm was measured.
The integrity of the RNA was assessed by denaturing agarose
gel electrophoresis.
The RNA (0.75μg from each sample) was reverse tran-
scribed at 42◦Cf o r1h o u ri n3 0 μL containing 300 units
of Superscript II Rnase H−reverse transcriptase (Invitrogen
Life Technologies), 7μM anchored oligo dT13VN, 50mMAlexandra Bukovsk´ ae ta l . 3
Table 2: Oligonucleotide primers for real-time PCR.
Gene namea Primer sequence (5 -3 )b Tac(◦C) Tacqd(◦C)
IL-1β FP: AAGTGATATTCTCCATGAGCTTTGT 64 82
RP: TTCTTCTTTGGGTATTGCTTGG
IL-6 FP: TGGGAAATCGTGGAAATGAG 66 80
RP: CTCTGAAGGACTCTGGCTTTG
IL-10 FP: CAACATACTGCTAACCGACTCCT 66 82
RP: TGAGGGTCTTCAGCTTCTCAC
TNFα FP: CGTCGTAGCAAACCACCAAG 64 80
RP: TTGAAGAGAACCTGGGAGTAGACA
GM-CSF FP: GCAATTTCACCAAACTCAAGG 64 82
RP: CTCATTACGCAGGCACAAAAG
IFNγ FP: ATCAGGCCATCAGCAACAAC 62 82
RP: ATCAGCAGCGACTCCTTTTC
β-actin FP: AAATCGTGCGTGACATCAAAG 70 82
RP: AAGAAGGAAGGCTGGAAAAGAG
HPRT FP: TGGATACAGGCCAGACTTTGTT 68 80
RP: ACTTGCGCTCATCTTAGGCTTT
SDHA FP: CATGCCAGGGAAGATTACAAAG 65 80
RP: AGTAGGAGCGGATAGCAGGAG
a IL, interleukin; TNFα, tumor necrosis factor alpha; GM-CSF, granulocyte-macrophage colony stimulating factor; IFNγ, interferon gamma; β-actin, beta
actin; HPRT, hypoxanthine guanine phosphoribosyl transferase 1; SDHA, succinate dehydrogenase complex subunit A
b F P ,f o r w a r dp r i m e r ;R P ,r e v e r s ep r i m e r
c Ta, annealing temperatures used for thermal cycling
d Tacq, temperature at which the ﬂuorescence signal was acquired (“acquiring temperature”)
Tris-HCl pH 8.3, 3mM MgCl2,7 5 m MK C l ,1 0 m MD T T ,
500μM dNTPs (dATP, dTTP, dCTP, dGTP), 60 units RNase
OUT (recombinant ribonuclease inhibitor, Invitrogen Life
Technologies), and 0.75μg acetylated BSA. The reaction was
terminated by heating at 95◦Cf o r5m i n u t e s .T oc h e c kf o r
the presence of genomic DNA contamination in the RNA
preparations, reverse transcriptase negative control (no re-
versetranscriptaseinthereaction)wascarriedoutinparallel,
using RNA pool prepared from aliquots of all RNA samples.
The pool of colon RNA obtained from aliquots of all sam-
ples served as standard RNA. The relative standard curve was
generated using Mx 3000P 2.0 software (Stratagene, La Jolla,
Calif).
PCR reactions were carried out in a 20μLﬁ n a lv o l u m e
in duplicates using SYBRGreen I as a ﬂuorescent detection
dye. The reactions contained 0.8μL of cDNA (correspond-
ing to 20ng of sample total RNA), one unit of platinum
Taq DNA polymerase (Invitrogen Life Technologies), SYBR-
Green I in ﬁnal dilution of 1 : 25000 (Sigma-Aldrich, Mu-
nich, Germany), 30nM ROX (passive reference dye for cor-
rection of non-PCR-related ﬂuctuations in ﬂuorescence sig-
nal,Stratagene),0.2mMdNTPs(dATP,dTTP,dCTP,dGTP),
50mM KCl, 10mM Tris-HCl pH 8.3, 2.5mM MgCl2(except
fortheβ-actinreaction,where1.5mMMgCl2 wasused),for-
ward and reverse primers in ﬁnal concentration of 0.25μM
(for IL-1β, IL-12b, TNFα,I F N - γ, HPRT, and SDHA), or 0.5
μM (for IL-6, IL-10, GM-CSF, and β-actin; see Table 2 for
full gene names). Oligonucleotide primers used in the exper-
iment were designed in our previous work [34], and their
sequences are shown in Table 2. PCR ampliﬁcation was per-
formed in the real-time PCR system Mx 3000P (Stratagene).
Afteraninitialstepat95◦Cfor2minutes(DNAdenaturation
andhot-startDNApolymeraseactivation),40cycleswiththe
following thermocycling conditions were carried out: 94◦C
for 30 seconds, speciﬁc annealing temperature for 30 sec-
onds, 72◦C for 30 seconds, and speciﬁc temperature at which
the ﬂuorescence was acquired (“acquiring temperature”) for
30 seconds. Measurement of ﬂuorescence at an elevated tem-
perature (“acquiring temperature,” a few degrees of Celsius
below the melting temperature of the speciﬁc PCR prod-
uct) enables elimination of the ﬂuorescence signal produced
by incidental short nonspeciﬁc PCR products. Ampliﬁcation
speciﬁcity was then checked by generation of a melting curve
using 41 cycles with temperature increments of 1◦C (starting
with 55◦C) and a ﬂuorescence measurement in each cycle.
Speciﬁc annealing and acquiring temperatures are shown in
Table 2.
To ensure the correctness of the quantiﬁcation, we nor-
malizedcytokineexpressiontotheexpressionofthreehouse-
keeping genes. Firstly, expression stability of several house-
keeping genes was tested using geNorm software [35]. Sub-
sequently, the normalization factor for each sample was cal-
culated (by geNorm software) as the geometric means of
the relative amounts of the three most stable housekeeping
genes—HPRT, SDHA, and β-actin (see Table 2 for full gene
names). Finally, the relative amount of cytokine mRNA in
each sample was divided by the normalization factor of the
sample.4 Mediators of Inﬂammation
2.4. QuantiﬁcationofcytokineproteinbyELISA
Colontissuesampleswerehomogenizedinice-coldPBScon-
taining protease inhibitor cocktail for use with mammalian
cell and tissue extracts (P8340, Sigma-Aldrich), and the ho-
mogenates were then centrifuged at 12000xg at 4◦Cf o r1 5
minutes. Total protein amounts in the tissue supernatants
were determined using Bradford protein assay [36]wi t hB S A
employed as the standard. IL-1β and IL-6 amounts were de-
terminedusinganELISAkit,accordingtothemanufacturer’s
recommendation (Pierce-Endogen, Rockford, Ill, USA).
2.5. Statisticalanalysis
The Kruskal-Wallis test and the Mann-Whitney U test were
used for the estimation of macroscopic damage scores. The
chi-square test was used to assess diﬀerences in mortality
rate. The Student t test was used for the comparison of dif-
ferences in body weight. The Kruskal-Wallis test was used for
thecomparisonofdiﬀerencesincytokineexpressionbetween
groups and the Mann-Whitney U test was used to compare
diﬀerences between the group of untreated colitic animals
and other groups of animals. Values of p<. 05 were con-
sidered as signiﬁcant.
3. RESULTS
3.1. Bodyweightchanges,mortality,and
macroscopicdamagescores
As shown in Figure 1, administration of TNBS caused a dra-
matic decrease in body weight (almost 20% after 3 days);
body weightwasrecoveredgraduallyfromday4butnot fully
to the initial weight in day 7. Mice receiving 50% ethanol
without TNBS (control sham group) showed only slight and
transient loss of body weight. In mice of group B (colitic
animals treated with 0.2% thyme and 0.1% oregano oils),
body weight was recovered gradually from day 3 when it be-
came higher than the body weight of untreated colitic an-
imals (group D); on day 7, the body weight of animals in
groupBreachedalevelneartothatofthecontrolmice(sham
group). The body weight of mice in group A (colitic animals
treatedwith0.4%thymeand0.2%oreganooils)andgroupC
(colitic animals treated with 0.1% thyme and 0.05% oregano
oils) did not diﬀer signiﬁcantly from that of untreated colitic
animals (group D).
The mortality rate of mice with TNBS-induced colitis
(group D) was 53.3%, while that of the control sham group
was 0% (see Figure 2). The mortality rate in group A (colitic
animals treated with 0.4% thyme and 0.2% oregano oils) was
50%andingroupC(coliticanimalstreatedwith0.1%thyme
and 0.05% oregano oils) was 62.5%, which are comparable
to that found in group D. Treatment with the combination
of 0.2% thyme and 0.1% oregano oils (group B) decreased
the mortality rate to 33.3% (which was still not signiﬁcantly
diﬀerent from that of mice with TNBS-induced colitis).
Macroscopic damage scores of mice in group D were
signiﬁcantly higher than those of mice in the control sham
group. Treatment with the combination of 0.2% thyme and
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Figure 1: Body weight changes. Changes in body weight are ex-
p r e s s e da sap e r c e n t a g eo ft h eo r i g i n a lw e i g h to nd a y0 .V a l u e s
are arithmetical means ± SEM. Statistical signiﬁcance of the diﬀer-
ences between the group of untreated colitic animals (TNBS group)
and other groups of animals was assessed using the Student t test;
∗P ≤ .05, ∗∗P ≤ .01, ∗∗∗P ≤ .001. A (): colitic animals fed with
the combination of 0.4% thyme and 0.2% oregano oils; B (): col-
itic animals fed with the combination of 0.2% thyme and 0.1%
oregano oils; C (•): colitic animals fed with the combination of
0.1% thyme and 0.05% oregano oils; D (): animals with TNBS-
induced colitis; E (◦), control sham animals; a: statistical diﬀerence
between the D and E groups; b: statistical diﬀerence between the D
and B groups.
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A( 8 /16)
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C( 6 /16)
D( 7 /16)
E( 1 3 /13)
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Figure 2: Mortality rate. Results are shown as the percentage of
dead animals in each experimental group.Values in parentheses in-
dicate the number of surviving animals compared with the total
number of animals 7 days after induction of TNBS colitis. A, col-
itic animals fed with the combination of 0.4% thyme and 0.2%
oregano oils; B, colitic animals fed with the combination of 0.2%
thyme and 0.1% oregano oils; C, colitic animals fed with the com-
bination of 0.1% thyme and 0.05% oregano oils; D, animals with
TNBS-induced colitis; E, control sham animals.
0.1%oreganooils(groupB)signiﬁcantlyloweredthemacro-
scopic damage scores in comparison to untreated colitic an-
i m a l s( g r o u pD ) .A n i m a l si ng r o u p sAa n dCs h o w e dn o
signiﬁcant changes in macroscopic damage scores compared
with mice in group D (see Figure 3).
Representative samples of colon after hematoxylin and
eosinstainingsareshowninFigure 4.Thereisnoevidenthis-
tologicalmodiﬁcationinshammice(E).InmicewithTNBS-
induced colitis (D), there is a wide range of histopathologi-
cal changes including necrosis of epithelium, destruction of
glands, and inﬁltration of inﬂammatory cells in the mucosaAlexandra Bukovsk´ ae ta l . 5
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Figure 3: Colonic tissue damage. Macroscopic damage scores were
assessed using Wallace’s colon macroscopic scoring system (31).
Values are arithmetical means + SEM, n = 6 − 13. Statistical sig-
niﬁcance was assessed using the Kruskal-Wallis test (K-W, diﬀer-
ences between all groups of animals) and Mann-Whitney test (dif-
ference between group D and other groups of animals). ∗P ≤ .05,
∗∗∗P ≤ .001. A, colitic animals fed with the combination of 0.4%
thyme and 0.2% oregano oils; B, colitic animals fed with the com-
bination of 0.2% thyme and 0.1% oregano oils; C, colitic animals
fed with the combination of 0.1% thyme and 0.05% oregano oils;
D, animals with TNBS-induced colitis; E, control sham animals.
and submucosa (up to 50% of colon section). The samples
from mice treated with 0.2% thyme and 0.1% oregano oils
(B)showintermediaryhistopathologicalchanges(upto30%
of colon section).
3.2. ExpressionofcytokinemRNA
Relative amounts of IL-1β, IL-6, GM-CSF, and TNFα mR-
N A s( f o rf u l lg e n en a m e s ,s e eTable 2) were signiﬁcantly
higher in animals with TNBS-induced colitis (group D) than
in the control sham-treated animals (see Figure 5). Treat-
ment of the colitic animals with the combination of thyme
and oregano oils signiﬁcantly lowered the amount of IL-1β
mRNA, using all three tested doses of the aromatic oils (see
Figure 5). The amount of IL-6 mRNA in group B (colitic an-
imals treated with 0.2% thyme and 0.1% oregano oils) was
signiﬁcantly lower than that in the group D, whereas the de-
crease of IL-6 mRNA level in groups A and C (colitic an-
imals treated with 0.4% thyme and 0.2% oregano oils or
with 0.1% thyme and 0.05% oregano oils) was not statis-
tically signiﬁcant (see Figure 5). A similar eﬀect was found
for GM-CSF and TNFα but the diﬀerence between group B
and group D did not reach statistical signiﬁcance (p = .064
and p = .053, resp.; see Figure 5). We found no signiﬁcant
changes in mRNA levels of two other cytokines (IL-10 and
IFNγ,d a t aw e r en o ts h o w n ) .
3.3. ExpressionofIL-1βandIL-6proteins
AsshowninFigure 6,theamountsofIL-1βandIL-6proteins
were signiﬁcantly higher in the animals with TNBS-induced
colitis (group D) than in the control sham group. The con-
centrations of these proteins were signiﬁcantly reduced in
(a)
(b)
(c)
Figure 4: Histological appearance of mouse colonic tissue. Rep-
resentative samples of colon after hematoxylin and eosin staining
are shown. (a) Sham group; (E): no evident histological modi-
ﬁcation. (b) Mice with TNBS-induced colitis; (D) a wide range
of histopathological changes including necrosis of epithelium, de-
struction of glands, and inﬁltration of inﬂammatory cells in the
mucosa and submucosa (up to 50% of colon section). (c) Mice
treated with 0.2% thyme and 0.1% oregano oils; (B) intermediary
histopathological changes (up to 30% of colon section).
group B (colitic animals treated with 0.2% thyme and 0.1%
oregano oils) compared to group D. The levels of IL-1β and
IL-6 proteins in groups A and C (colitic animals treated with
0.4% thyme and 0.2% oregano oils or with 0.1% thyme and
0.05% oregano oils) did not diﬀer signiﬁcantly from those
found in group D (see Figure 6).6 Mediators of Inﬂammation
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Figure 5: Cytokine mRNA expression. Relative amounts of a cytokine mRNA in each sample were divided by the normalization factor
(geometric means of HPRT, SDHA and, β-actin amount) of the sample. Values are arithmetical means + SEM, n = 6 − 8. Statistical
signiﬁcance was assessed using the Kruskal-Wallis test (K-W, diﬀerences between all groups of animals) and Mann-Whitney test (diﬀerence
between group D and other groups of animals); ∗P ≤ .05, ∗∗P ≤ .01, ∗∗∗P ≤ .001. A, colitic animals fed with the combination of 0.4%
thyme and 0.2% oregano oils; B, colitic animals fed with the combination of 0.2% thyme and 0.1% oregano oils; C, colitic animals fed with
the combination of 0.1% thyme and 0.05% oregano oils; D, animals with TNBS-induced colitis; E, control sham animals.
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Figure 6: IL-1β and IL-6 protein expression. Values are arithmetical means + SEM, n = 6 − 8. Statistical signiﬁcance was assessed using the
Kruskal-Wallis test (K-W, diﬀerences between all groups of animals) and Mann-Whitney test (diﬀerence between group D and other groups
of animals); ∗∗P ≤ .01, ∗∗∗P ≤ .001. A, colitic animals fed with the combination of 0.4% thyme and 0.2% oregano oils; B, colitic animals fed
with the combination of 0.2% thyme and 0.1% oregano oils; C, colitic animals fed with the combination of 0.1% thyme and 0.05% oregano
oils; D, animals with TNBS-induced colitis; E, control sham animals.
4. DISCUSSION
Various aromatic plants and their products have been re-
ported to have health beneﬁt properties. In this study, we
examined whether dietary supplementation with a combi-
nation of thyme essential oil and oregano essential oil could
have a protective eﬀect in intestinal inﬂammation. We ap-
plied three doses of thyme and oregano essential oil combi-
nation (0.4% thyme and 0.2% oregano oils, 0.2% thyme and
0.1% oregano oils, 0.1% thyme and 0.05% oregano oils) to
mice with TNBS-induced colitis, and found that administra-
tion of the medium dose decreased the mortality rate from
53% to 33%, signiﬁcantly accelerated the body weight gain
recovery, and signiﬁcantly reduced the macroscopic dam-
age of the colonic tissue. In animals fed with the two other
doses of the essential oils, we did not ﬁnd a signiﬁcantAlexandra Bukovsk´ ae ta l . 7
improvement in the mortality rate, body weight gain recov-
ery, or colonic tissue damage.
Examining the expression of cytokines, we found signif-
icantly elevated mRNA levels of proinﬂammatory cytokines
IL-1β,IL-6,GM-CSF,andTNFαinmicewithTNBS-induced
colitis. This ﬁnding is in agreement with other studies show-
ing increased expression of proinﬂammatory cytokines in
mouseexperimentalmodelsofcolitis[4–7].Treatmentofthe
colitic animals with the medium dose of aromatic oils (0.2%
thymeand0.1%oreganooils)decreasedthemRNAamounts
of IL-1β, IL-6, GM-CSF, and TNFα (in GM-CSF and TNFα,
the diﬀerence did not reach statistical signiﬁcance). Other
two doses (0.4% thyme and 0.2% oregano oils; 0.1% thyme
and 0.05% oregano oils) were less eﬀective and the diﬀerence
in cytokine mRNA level between animals treated with these
doses of the aromatic oils and untreated colitic animals was
signiﬁcant only in the case of IL-1β.
The most sensitive indicators of the eﬀectiveness of the
thyme and oregano oil treatment were mRNA levels of
proinﬂammatory cytokines IL-1β and IL-6 in our experi-
ment. Similarly, Kwon et al. [7] demonstrated that plant
ﬂavonoidrutinadministeredindiettomicewithdextransul-
fate sodium (DSS)-induced colitis signiﬁcantly suppressed
mRNA levels of IL-1β and IL-6, whereas the eﬀect on mRNA
level of GM-CSF was less marked. Increase of IL-1β and IL-6
mRNA levels in inﬂamed intestinal tissue has been well doc-
umented [12–14], and there are data indicating that IL-1β
can stimulate production of IL-6 in intestinal epithelial cells
[37, 38]. Reported data about the expression of TNFα are
somewhat contradictory, showing either no change or an in-
crease of TNFα levels in intestinal inﬂammation [10]. Sugi-
moto et al. [4] showed that elevated levels of TNFα mRNA
in mice with TNBS-induced colitis can be suppressed by cur-
cumin treatment, but Kwon et al. [7] found no signiﬁcant
changes in TNFα mRNA levels in mice with DSS-induced
colitis (treated or untreated with plant ﬂavonoid rutin).
Examination of IL-1β and IL-6 protein expression in our
experiment conﬁrmed the best eﬃcacy of the medium dose
of thyme and oregano oil combination in the suppression
of colitis. The cytokine protein level in animals treated with
the medium dose, but not in animals treated with the other
two doses, was signiﬁcantly lower than in the untreated col-
itic animals. The low eﬀectiveness in attenuating the colitis
found after administration of the highest dose of thyme and
oregano oil combination could be connected with possible
cytotoxic eﬀects of higher concentrations of these oils. In our
preliminaryexperimentswithintactmice,wefoundnegative
eﬀects of higher concentrations of thyme essential oil (1%)
andoreganoessentialoil(0.5%)onbodyweightandfoodin-
take. Moreover, the cytotoxic eﬀect of higher concentrations
of these oils has been demonstrated in intestinal cells and
lymphocytes [39, 40]. Thus, the lack of the dose dependency
found in this study could be due to a combination of positive
and negative eﬀects of the highest concentration of thyme
and oregano essential oil combination. On the other hand,
toolowdosesofessentialoilscanbeinsuﬃcienttoreducethe
intensity ofinﬂammation.Asimilarphenomenonwasfound
in the study examining the protective eﬀects of curcumin on
TNBS-inducedcolitisinmice,wherethemediumtesteddose
was more eﬀective at improving body weight gain than the
lower or higher doses of curcumin. To explain the lack of the
dose dependency, authors speculated about curcumin toxic-
ity or about the inﬂuence on the food intake [4]. Thus, the
use of optimal doses is essential for good eﬃcacy of essential
oils(ortheircomponents)inattenuatinginﬂammation.Fur-
ther experiments are needed to establish the most eﬃcient
concentration of thyme and oregano essential oil combina-
tion.
In our preliminary experiments (using similar experi-
mental conditions as in the present study), we administered
thyme (0.5%, 0.25%, 0.12%) or oregano (0.4, 0.2%, 0.1%)
essential oil alone in diet to mice with TNBS-induced coli-
tis and we found no signiﬁcant positive eﬀect. Furthermore,
we observed negative eﬀects on body weight and food intake
with oregano at 0.4% concentration. However, we observed
a better recovery of body weight after treatment with a com-
bination of these essential oils in preliminary tests. The re-
sults of the present study conﬁrm the positive eﬀects of the
combined administration of appropriate concentrations of
thymeandoreganooilsonTNBS-inducedcolitis.Itisknown
that oregano essential oil possesses strong antimicrobial ac-
tivity, which is ascribed to carvacrol, the main component of
this oil [41]. Thymol, one of the major compounds of thyme
essential oil, has anti-inﬂammatory activity [21]. Thus, it
seems that major components of these oils can complement
one another, having synergic eﬀects on inﬂammation so that
their combination could exhibit positive preventive or ther-
apeutic eﬀects. A similar phenomenon was found in another
study where the eﬀect of peppermint oil and caraway oil on
postinﬂammatory visceral hyperalgesia was examined (using
a rat model of TNBS-induced colitis). Neither peppermint
nor caraway oil administered individually had a signiﬁcant
eﬀect on postinﬂammatory visceral hyperalgesia, but com-
binedtreatmentwiththeseessentialoilssigniﬁcantlyreduced
the visceromotor response [42].
Mechanisms mediating the suppressive eﬀects of thyme
and oregano oils on colitis are unclear, and we can only spec-
ulate that there are several potential manners of action. One
possibility could be the inﬂuence of the essential oils on nu-
clear factor κB( N F - κB), a pleiotropic transcription factor
which can activate expression of genes involved in immune
and inﬂammation responses such as proinﬂammatory cy-
tokines[43].Severalstudieshavedemonstratedaninhibitory
eﬀect of various plant extracts or their components on NF-
κB activation. Suppression of the NF-κB inhibitory protein
(IκB)degradationincolonicepithelialcellsandmacrophages
was demonstrated after the administration of curcumin and
zerumbone [4,44,45].ReducedactivationofNF-κBwasalso
shown after treatment with black tea polyphenol theaﬂavin
in RAW 264.7 cells [46]. On the other hand, IL-1β (such as
other proinﬂammatory cytokines) is a potent inducer of NF-
κB[ 43] and it has been shown that extract of Thymus pule-
gioides can inhibit activation of NF-κBb yI L - 1 β in human
hepatoma cells [47].
In conclusion, the present data indicate that dietary ad-
ministration of a combination of thyme and oregano essen-
tialoilsinappropriateconcentrationscanreducetheproduc-
tion of proinﬂammatory cytokines and attenuate the degree8 Mediators of Inﬂammation
of colonic tissue injury, and thereby ameliorate TNBS-
induced colitis in mice. We suggest that the combination of
thymeandoreganoessentialoilshaspotentialvalueasanad-
ditional or supporting treatment in gastrointestinal inﬂam-
mations. Our results indicate that some essential oils could
have positive eﬀects on TNBS-induced colitis but seemingly
in rather narrow range of concentrations, thus limiting their
therapeutic/preventive potential.
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